CART-ddBCMA for multiple myeloma: Interim results from phase I study

被引:1
|
作者
Frigault, M. [1 ]
Rosenblatt, J. [2 ]
Raje, N. [1 ]
Cook, D. [1 ]
Gaballa, M. [3 ]
Emmanuel-Alejandro, E. [1 ]
Cornwell, C. [4 ]
Banerjee, K. [4 ]
Rotte, A. [4 ]
Heery, C. [5 ]
Avigan, D. [2 ]
Jakubowiak, A. [6 ]
Bishop, M. [6 ]
机构
[1] MGH Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[2] Beth Israel Deaconess Med Ctr, Canc Ctr, Boston, MA USA
[3] Massachusetts Gen Hosp, Canc Ctr, Surg Oncol Div, Boston, MA USA
[4] Arcellx, Clin & Regulatory Affairs, Gaithersburg, MD USA
[5] Arcellx, Clin Dev Dept, Gaithersburg, MD USA
[6] Univ Chicago Med, Canc Ctr, Chicago, IL USA
关键词
D O I
10.1016/j.annonc.2022.07.746
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
620O
引用
收藏
页码:S828 / S828
页数:1
相关论文
共 50 条
  • [1] Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma.
    Frigault, Matthew J.
    Rosenblatt, Jacalyn
    Daniella, Cook
    Cho, Ha Na
    Depinho, Gabriel D.
    Logan, Emma
    Liegel, Jessica
    Prabhakar, Yougeesh
    Cornwell, Christine
    Banerjee, Kamalika
    Rotte, Anand
    Heery, Christopher Ryan
    Avigan, David
    Jakubowiak, Andrzej J.
    Bishop, Michael Russell
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
    Frigault, Matthew J.
    Bishop, Michael R.
    Rosenblatt, Jacalyn
    O'Donnell, Elizabeth K.
    Raje, Noopur
    Cook, Daniella
    Yee, Andrew J.
    Logan, Emma
    Avigan, David E.
    Jakubowiak, Andrzej
    Shaw, Kit
    Daley, Heather
    Nikiforow, Sarah
    Griff, Faith
    Cornwell, Christine
    Shen, Angela
    Heery, Christopher
    Maus, Marcela V.
    BLOOD ADVANCES, 2023, 7 (05) : 768 - 777
  • [3] Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and/or Refractory Multiple Myeloma
    Frigault, Matthew
    Rosenblatt, Jacalyn
    Dhakal, Binod
    Raje, Noopur
    Cook, Daniella
    Gaballa, Mahmoud R.
    Emmanuel-Alejandro, Estelle
    Nissen, Danielle
    Cornwell, Christine
    Banerjee, Kamalika
    Rotte, Anand
    Heery, Christopher R.
    Avigan, David
    Jakubowiak, Andrzej
    Bishop, Michael R.
    BLOOD, 2022, 140 : 7439 - 7440
  • [4] Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients
    Frigault, Matthew J.
    Rosenblatt, Jacalyn
    Dhakal, Binod
    Raje, Noopur S.
    Cook, Daniella
    Gaballa, Mahmoud
    Emmanuel-Alejandro, Estelle
    Nissen, Danielle
    Banerjee, Kamalika C.
    Rotte, Anand
    Heery, Christopher R.
    Avigan, David
    Jakubowiak, Andrzej J.
    Bishop, Michael R.
    BLOOD, 2023, 142
  • [5] Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma
    Frigault, Matthew J.
    Bishop, Michael R.
    O'Donnell, Elizabeth K.
    Raje, Noopur S.
    Mondillo, Allegra
    Cook, Daniella
    Daley, Heather
    Mangus, Carissa
    LeFleur, David W.
    Buonato, Janine M.
    Edwards, Justin P.
    Richman, Laura K.
    Polianova, Maria T.
    Sabatino, Maria
    Currence, Scott
    Shen, Angela
    Quigley, Travis
    Maus, Marcela V.
    BLOOD, 2020, 136
  • [6] Phase 1 study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain for the treatment of subjects with relapsed and refractory multiple myeloma
    Frigault, Matthew
    Rosenblatt, Jacalyn
    Raje, Noopur
    Cook, Daniella
    Gaballa, Mahmoud
    Emmanuel-Alejandro, Estelle
    Cornwell, Christine
    Banerjee, Kamalika
    Rotte, Anand
    Heery, Christopher
    Avigan, David
    Jakubowiak, Andrzej
    Bishop, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S2 - S2
  • [7] Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.
    Frigault, Matthew J.
    O'Donnell, Elizabeth
    Raje, Noopur S.
    Cook, Daniella
    Yee, Andrew
    Rosenblatt, Jacalyn
    Gibson, Chelsey
    Logan, Emma
    Avigan, David
    Bishop, Michael Russell
    Eckert, Katherine
    Daley, Heather
    Rodriguez, Diego Hernandez
    Mason, Andrew
    Nikiforow, Sarah
    Mangus, Carissa
    Gil-Krzewska, Aleksandra
    Currence, Scott
    Shen, Angela
    Maus, Marcela Valderrama
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Positive interim results from Phase I/II multiple myeloma cancer vaccine trial
    Riedmann, Eva M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (06) : 696 - 697
  • [10] Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study
    Richardson, Paul G.
    Moreau, Philippe
    Jakubowiak, Andrzej J.
    Facon, Thierry
    Jagannath, Sundar
    Vij, Ravi
    Reece, Donna E.
    White, Darrell J.
    Raab, Marc S.
    Benboubker, Lotfi
    Rossi, Jean-Francois
    Tsao, Claire
    Fry, John
    Berman, David
    Singhal, Anil K.
    Lonial, Sagar
    BLOOD, 2010, 116 (21) : 434 - 434